Managing the TME to improve the efficacy of cancer therapy

Front Immunol. 2022 Oct 20:13:954992. doi: 10.3389/fimmu.2022.954992. eCollection 2022.

Abstract

The tumor microenvironment (TME) influences tumor growth, metastatic spread and response to treatment. Often immunosuppression, mediated by the TME, impairs a beneficial response. The complexity of the tumor composition challenges our abilities to design new and more effective therapies. Going forward we will need to 'manage' the content and or functionality of the TME to improve treatment outcomes. Currently, several different kinds of treatments are available to patients with cancer: there are the traditional approaches of chemotherapy, radiation and surgery; there are targeted agents that inhibit kinases associated with oncogenic pathways; there are monoclonal antibodies that target surface antigens often delivering toxic payloads or cells and finally there are antibodies and biologics that seek to overcome the immunosuppression caused by elements within the TME. How each of these therapies interact with the TME is currently under intense and widespread investigation. In this review we describe how the TME and its immunosuppressive components can influence both tumor progression and response to treatment focusing on three particular tumor types, classic Hodgkin Lymphoma (cHL), Pancreatic Ductal Adenocarcinoma (PDAC) and Glioblastoma Multiforme (GBM). And, finally, we offer five approaches to manipulate or manage the TME to improve outcomes for cancer patients.

Keywords: GBM - glioblastoma multiforme; Hodgkin (cHL); PDAC - pancreatic ductal adenocarcinoma; TME (tumor microenvironment); anti-cancer therapy; immunosuppression; immunotherapy combined therapy.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antineoplastic Agents, Immunological* / therapeutic use
  • Carcinoma, Pancreatic Ductal* / pathology
  • Humans
  • Immunotherapy
  • Pancreatic Neoplasms* / pathology
  • Tumor Microenvironment

Substances

  • Antineoplastic Agents, Immunological